Recordati Pharma GmbH Germany

Dr Dankwart Rauscher
Head of Licensing and Business Development 

Redx Pharma plc United Kingdom

Redx Pharma discovers and develops proprietary, small molecule drugs to address areas of high unmet medical need in cancer and fibrosis. In cancer, we pursue targeted therapies where a biomarker can potentially be used for selecting those patients that are most likely to benefit from therapy, and/or drugs that are designed to disrupt cancer resistance pathways. In fibrosis, we are focused on developing treatments that will stop and reverse the formation of fibrotic tissue. In both therapeutic areas we aim to develop drugs whose profile suggests they will be best in class, if not first in class

Mr Nicholas Adams
CBO 

Riemser Pharma GmbH Germany

RIEMSER Pharma GmbH is a European specialty pharmaceutical company established in December 1992 with core competencies focused niche therapy areas with high unmet medical need.

RIEMSER markets its own product portfolio in numerous therapeutic areas including oncology, neurology, anti-infectives and dermatology.

RIEMSER is present with own affiliates in Germany, France and UK and is selling its products in > 60 countries worldwide through a network of trusted partners.

We are looking to strengthen our portfolio through licensing or acquisition.

Ms Magdalena Poznanski
Ms Magdalena Poznanski
Business Development Manager 

Sanofi France

Mr Eric Moussaud-Fergeau
Mr Eric Moussaud-Fergeau
LinkedIn logo Out-Licensing Business Development & Licensing 

Sanofi Group Germany

Dr Oliver Freichel
Head of Global CHC Business Development & Strategy 

SANOFI-AVENTI GROUP France

Mrs Laurence CASSARINO
Licensing-out Lead - Portfolio Enhancement & Maximisation Dpt 

Sanova Pharma GesmbH Austria

Mr Alexander Burstein
Head of business development 

Santen Germany

Dr Robert Bauer
Director, Business Development EMEA 

SBA Ltd United Kingdom

Specialties: Business Development, Licensing and Market Research support, Alliance Management and Customer Relations to the Biotech, Medtech, Pharmaceutical and Life Sciences Industries, and Start-Up Coaching.

www.linkedin.com/in/simon-bennett-0390796

1.  Looking for co-investment opportunities under TPI's i2020 Accelerator scheme: early-stage, seed round, small molecule focus

2.  Looking for assets for licensing for clients, including: rare disease assets (except cell & gene therapy), CVD, pain management, respiratory, innovative technologies, 505(b)(2) products

3.  Meeting companies interested in state-of-the -art machine learning solutions for drug discovery

4.  Meeting companies interested in acquiring antibody libraries

5.  Meeting companies interested in acquiring a phase II ready asset in multiple myeloma

6.  Meeting companies interested in a range of market-ready nickel allergy products

Dr Simon Bennett
Dr Simon Bennett
Managing Director 

Sebela United States

Mr Jai Wall
VP